Physician profile
Patricia Li
NPI 1003579830
$5,540.65
in general payments reported to CMS, 2019-2025
29 companies · $598 in 2025
The $598 reported for 2025 was more than what 78% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $398 · 2022: $1,609 · 2023: $1,843 · 2024: $1,093 · 2025: $598.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,512 · Entertainment: $21.48.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,512.08 |
| Entertainment | $21.48 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $1,013.02 | 2021-2025 | Yeztugo |
| Abbvie INC. | $911.00 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $849.63 | 2022-2025 | Farxiga, Airsupra, Breztri |
| Viiv Healthcare Company | $601.04 | 2021-2025 | Cabenuva, Apretude |
| Janssen Biotech, INC. | $517.68 | 2021-2023 | Symtuza |
| Janssen Products, LP | $186.16 | 2021-2022 | |
| Pfizer INC. | $177.93 | 2023 | |
| Novo Nordisk INC | $170.47 | 2022-2024 | Ozempic, Rybelsus, Wegovy |
| Merck Sharp & Dohme LLC | $139.31 | 2023-2025 | Pifeltro, Capvaxive, Gardasil 9 |
| Biohaven Pharmaceuticals, INC. | $113.03 | 2021 | |
| Alexion Pharmaceuticals, INC. | $105.16 | 2021 | |
| Dynavax Technologies Corporation | $101.67 | 2022-2023 | Heplisav-B |
| Janssen Scientific Affairs, LLC | $96.40 | 2023 | Symtuza |
| Boehringer Ingelheim Pharmaceuticals, INC. | $73.14 | 2023-2024 | Jardiance |
| Hologic Sales and Service, LLC | $64.80 | 2022-2023 | Aptima |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $51.93 | 2024-2025 | Krystexxa, Otezla, Repatha |
| Janssen Pharmaceuticals, INC | $49.23 | 2024 | Spravato |
| Abbott Laboratories | $45.57 | 2023-2024 | Freestyle Libre 2, Proclaim |
| Glaxosmithkline, LLC. | $39.96 | 2022-2023 | Trelegy Ellipta |
| Exact Sciences Corporation | $31.16 | 2023-2025 | Cologuard Collection Kit |
| Sanofi-Aventis U.S. LLC | $29.01 | 2024-2025 | |
| Lilly USA, LLC | $28.47 | 2022-2023 | Mounjaro |
| Novartis Pharmaceuticals Corporation | $24.88 | 2024 | |
| Nestle Healthcare Nutrition INC. | $24.13 | 2022 | |
| Medtronic, INC. | $22.09 | 2024 | Intellis Adaptivestim |
| Optos, INC. | $21.48 | 2023 | Oct Ophthalmoscope, Panoramic Ophthalmoscope, Nfc-700 |
| Verity Pharmaceuticals INC. | $18.99 | 2024 | Tlando |
| Napo Pharmaceuticals INC | $18.12 | 2025 | Mytesi |
| Teleflex LLC | $15.19 | 2024 | Urolift |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Patricia Li listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.